Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Pluristem Therapeutics downgrade details — to Hold at Maxim Group (1.13 -0.01)Maxim Group downgrades PSTI to Hold from Buy as co raised capital in a structured transaction (100% warrant coverage), and firm ests after fees of ~$16.5M providing a about year's worth of operating capital. The goods news is they got the cash even if the terms were dilutive. They are lowering their rating as firm is not in agreement with the company in terms of their clinical plans. Firm feels the CLI programs are not properly powered. Mgmt intends to leverage fast track pathways now available in Japan, Europe and firm would expect the U.S. to drive a CLI product to commercialization. While firm believes PSTI's allogeneic cell therapy is safe, the issue is will it really work in CLI and how can that be proven? Fast track pathways are designed to allow these «safe» therapies a more rapid pathway to the marketplace but the sponsor must demonstrate proof that it works. They do not believe the trial designs that the company is proposing can definitely answer this question in a variable disease like CLI.</td> </tr></table>"